Tom 12, Nr 6 (2018)
Wybrane problemy kliniczne
Opublikowany online: 2018-12-15
Wyświetlenia strony
7386
Wyświetlenia/pobrania artykułu
23027
Zespół jelita drażliwego w świetle najnowszych wytycznych
Forum Medycyny Rodzinnej 2018;12(6).
Streszczenie
Zespół jelita drażliwego jest częstą i nawracającą chorobą, która pomimo dobrego rokowania istotnie pogarsza jakość życia osób nią dotkniętych. Przyczyna choroby jest złożona i nie do końca wyjaśniona. Zespół jelita drażliwego jest przewlekłym schorzeniem przebiegającym z nawracającymi bólami brzucha związanymi z defekacją, zmianą rytmu wypróżnień lub zmianą konsystencji stolca. Aktualnie rozpoznanie tej choroby powinno być oparte na Kryteriach Rzymskich IV. Badania dodatkowe należy ograniczać do minimum. Niedawno zostały opublikowane nowe rekomendacje zarówno światowe jak i polskie przedstawiające aktualizację postępowania diagnostyczno-leczniczego w zespole jelita drażliwego, które zostały uwzględnione w tym opracowaniu.
Słowa kluczowe: zespół jelita drażliwegorozpoznawanieKryteria Rzymskie IVleczeniedorośli
Referencje
- Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016; 150(6): 1257–1261.
- Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and rome IV. Gastroenterology. 2016 [Epub ahead of print]; 150(6): 1262–1279.
- Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016; 150(6): 1393–1407.
- Pietrzak A, Skrzydło-Radomańska B, Mulak A, et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Rev. 2018; 13(4): 167–196.
- Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology. 2014; 146(6): 1500–1512.
- Simrén M, Barbara G, Flint HJ, et al. Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013; 62(1): 159–176.
- Mangell P, Nejdfors P, Wang M, et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci. 2002; 47(3): 511–516.
- Mangell P, Lennernäs P, Wang M, et al. Adhesive capability of Lactobacillus plantarum 299v is important for preventing bacterial translocation in endotoxemic rats. APMIS. 2006; 114(9): 611–618.
- Barbara G, Feinle-Bisset C, Ghoshal UC, et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016 [Epub ahead of print]; 150(6): 1305–1318.
- Boeckxstaens G, Camilleri M, Sifrim D, et al. Fundamentals of neurogastroenterology: physiology/motility — sensation. Gastroenterology. 2016 [Epub ahead of print]; 150(6): 1292–1304.
- Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015; 42(1): 3–11.
- Qin HY, Cheng CW, Tang XD, et al. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014; 20(39): 14126–14131.
- Sayuk GS, Gyawali CP. Irritable bowel syndrome: modern concepts and management options. Am J Med. 2015; 128(8): 817–827.
- Bartnik W, Chojnacki J, Paradowski L. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterol Klin. 2009; 1(1): 9–17.
- Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002; 122(4): 1140–1156.
- Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004; 126(7): 1665–1673.
- Johannesson E, Simrén M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011; 106(5): 915–922.
- Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014; 109(10): 1547–1561.
- Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001; 13(10): 1143–1147.
- Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30): 4012–4018.
- Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016; 61(2): 560–571.
- Rai RR, Dwivedi M, Kumar N. Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: a randomized double-blind placebo-controlled study. Saudi J Gastroenterol. 2014; 20(6): 378–382.
- Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol. 2015; 13(7): 1285–1292.
- Hou X, Chen S, Zhang Y, et al. Quality of life in patients with irritable bowel syndrome (IBS), assessed using the ibs-quality of life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783–793.
- Ducrotte P, Grimaud JC, Dapoigny M, et al. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014; 68(2): 245–254.
- Agger JL, Schröder A, Gormsen LK, et al. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study. Lancet Psychiatry. 2017; 4(5): 378–388.
- Talley NJ, Kellow JE, Boyce P, et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008; 53(1): 108–115.
- Pimentel M, Lembo A, Chey WD, et al. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364(1): 22–32.
- Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016; 151(6): 1113–1121.
- Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012; 107(1): 28–35.
- Bellini M, Usai-Satta P, Bove A, et al. ChroCoDiTE Study Group, AIGO. Chronic constipation diagnosis and treatment evaluation: the the CHRO.CO.DI.T.E. study. BMC Gastroenterol. 2017; 17(1): 11.
- Yang Y, Fang JY, Guo X, et al. Mo1646 efficacy and safety of linaclotide in patients with IBS-C: results from a phase 3, randomized, double-blind, placebo-controlled trial in china and other regions. Gastroenterology. 2016; 150(4): 741.
- Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018; 113(5): 735–745.
- Cryer B, Drossman DA, Chey WD, et al. Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders. Dig Dis Sci. 2017; 62(12): 3568–3578.
- Chang L, Chey WD, Drossman D, et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2016; 44(10): 1114–1122.
- Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016; 374(3): 242–253.
- Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001; 161(14): 1733–1740.
